कंपनी का अवलोकन
Assertio Holdings, Inc. operates as a pharmaceutical entity dedicated to delivering various therapeutic products to patients throughout the United States, with its portfolio notably including INDOCIN, an oral and suppository formulation designed to manage moderate to severe rheumatoid arthritis conditions, including acute flares of chronic disease and ankylosing spondylitis. The company functions within the broader Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, a classification that signifies its focus on developing and distributing niche medicinal compounds rather than mass-market consumer healthcare goods. As of the latest data, the firm holds a market capitalization of $116.14M and generates annual revenue of $118.71M, employing a workforce of 53 individuals to execute its operational and strategic objectives. These financial figures indicate that Assertio maintains a mid-cap profile with revenue levels that are significant relative to its employee base, suggesting a highly capital-efficient operational model where a small workforce supports nearly $119 million in total sales, though the market valuation reflects the speculative nature often associated with specialty drug manufacturers facing specific revenue headwinds.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $118.71M, yet recorded a net income loss of $30,375,000, while reporting an EBITDA of $12.78M. The substantial negative gap between the $118.71M in revenue and the $30.375M net loss reveals a highly aggressive cost structure or significant non-operating expenses that erode profitability despite positive earnings before interest, taxes, depreciation, and amortization. Free cash flow stands at -$16,582,250, indicating that the company is currently burning cash, which implies limited immediate financial flexibility and a reliance on existing cash reserves or external financing to sustain operations without immediate revenue infusion. The margin profile presents a stark contrast, with a gross margin of 70.2% demonstrating high efficiency in production and supply chain costs, yet an operating margin of -105.2% and a profit margin of -25.6% indicate that operating expenses and other costs far exceed gross profits, resulting in a bottom-line deficit. On the balance sheet, the company holds $63.41M in cash against $40.25M in debt, resulting in a debt-to-equity ratio of 42.84, which suggests a highly leveraged position where debt obligations are substantial relative to shareholders' equity. Despite the high leverage, the current ratio of 1.70 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting a manageable level of short-term liquidity risk. Return on Equity is recorded at -28.3% and Return on Assets at -3.9%, metrics that reveal management has yet to generate positive returns on the capital invested by shareholders or utilized in asset deployment, highlighting the challenges in translating operational activities into profitable outcomes during this period.
मूल्यांकन आकलन
The valuation metrics for Assertio Holdings, Inc. show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 2.51. The disparity between the unavailable trailing P/E and the low forward P/E of 2.51 implies that the market is pricing in a significant expected turnaround in earnings trajectory or is valuing the company based on future potential rather than historical profitability. The price-to-book ratio stands at 1.23, indicating that the market values the company at a 23% premium over its net book value, which may reflect intangible assets or growth expectations not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.98 and an EV/EBITDA of 7.28 suggest that the stock is trading at less than one dollar of market value for every dollar of sales, a metric often seen in cyclical or turnaround pharmaceutical firms. The stock has experienced significant volatility, with a 52-week high of $20.45 and a 52-week low of $7.65; based on the available data context, the stock is trading in a range that captures substantial downside from its recent peak, reflecting the high risk premium associated with its financial position. The beta value of 0.43 indicates that the stock exhibits low volatility relative to the broader market, moving at roughly 57% of the market's amplitude, which is somewhat atypical for a biotech firm but suggests that price movements are dampened by its specific operational characteristics or market cap size.
Growth & Income
Revenue growth year-over-year is reported at -57.9%, while earnings growth is N/A due to the current unprofitability. The contraction in revenue indicates a significant decline in sales volume or pricing power, and since the company is already unprofitable, the absence of earnings growth further underscores the difficulty in scaling operations without a fundamental shift in the business model. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no cash is distributed to shareholders, and instead, the firm retains its cash flow to fund operations, R&D, or debt repayment. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, positioning the asset as a speculative investment reliant entirely on future operational improvements rather than current cash generation or shareholder returns.